Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 21;19(7):1118-1121.
doi: 10.7150/ijms.72772. eCollection 2022.

Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials

Bo Liang  1   2 , Ning Gu  3
Affiliations
Review

Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials

Bo Liang et al. Int J Med Sci. .

Abstract

Heart failure coexists with type 2 diabetes mellitus, which seriously affects the clinical treatment and prognosis. At present, the treatment for patients with established heart failure and type 2 diabetes mellitus is usually combined with two treatment strategies for heart failure and type 2 diabetes mellitus. Recently, increasing studies showed that empagliflozin, a sodium-glucose co-transporter-2 inhibitor, has a positive effect on the treatment of patients with established heart failure and type 2 diabetes mellitus. Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations.

Keywords: SGLT2i; empagliflozin; heart failure; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Similar articles

See all similar articles

Cited by

References

    1. Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. The American Journal of Medicine. 2017;130:S40–S50. - PubMed
    1. Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A. et al. Heart failure in diabetes. Metabolism. 2021;125:154910. - PMC - PubMed
    1. Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J. et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:853–72. - PubMed
    1. Liang B, Zhao Y-X, Zhang X-X, Liao H-L, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol. 2020;19:55. - PMC - PubMed
    1. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85. - PubMed

MeSH terms